Risks stratification for invasive aspergillosis: Early assesment of host susceptibility

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Diagnosis; Epidemiology; Invasive aspergillosis; Non culture based diagnostics; Therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; GALACTOMANNAN; IMMUNOSUPPRESSIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; STEROID;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; ENZYME IMMUNOASSAY; FALSE POSITIVE RESULT; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOST SUSCEPTIBILITY; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INVASIVE ASPERGILLOSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; ZYGOMYCETES; DISEASE PREDISPOSITION; IMMUNE DEFICIENCY; REVIEW; RISK ASSESSMENT;

ASPERGILLOSIS; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNOCOMPROMISED HOST; RISK ASSESSMENT; RISK FACTORS;

EID: 67651123301     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780902718339     Document Type: Article

References (49)

1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-1025.
2. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711-727.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
4. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41 1448-1452.
5. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
6. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-3459.
7. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
8. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356: 409-411.
9. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19: 571-576.
10. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-260.
11. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824-1833.
12. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
13. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med 1998; 338: 1741-1751.
14. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
15. Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545-550.
16. Nucci M, Spector N, Bueno AP, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997; 24: 575-579.
17. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86 862-870.
18. Wald A, LeisenringW, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
19. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-351.
20. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (Suppl. 1): S49-58.
21. Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000; 2 22-28.
22. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
23. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-548.
24. Patterson TF, Peters J, Levine SM, et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40: 2217-2220.
25. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: Risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191-9.
26. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
27. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
28. Greene RE, Schlamm HT, Stark P, et al. Radiological findings in acute invasive pulmonary aspergillosis: Utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients (abstract O397). In: Program of the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, UK; May, 2003.
29. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-379.
30. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.
31. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-1610.
32. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.
33. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004; 190: 641-649.
34. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325-327.
35. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366-2367.
36. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.
37. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448-457.
38. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-5522.
39. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1--3)-beta-D-glucan assay for the diagnosis of invasive fungal infections - a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46: 1864-1870.
40. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
41. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-486.
42. Lass-Florl C, Gunsilius E, Gastl G, et al. Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses 2005; 48 (Suppl. 1): 12-17.
43. White PL, Archer AE, Barnes RA. Comparison of non-culturebased methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005; 43: 2181-2187.
44. Verweij PE, Klont RR, Donnelly JP. Validating PCR for detecting invasive aspergillosis. Br J Haematol 2004; 127: 235-236.
45. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still a ways to go. Clin Infect Dis 2006; 42: 487-489.
46. Gerson SL, Talbot GH, Lusk E, et al. Invasive pulmonary aspergillosis in adult acute leukemia: Clinical clues to its diagnosis. J Clin Oncol 1985; 3: 1109-1116.
47. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis 1987; 155: 12-27.
48. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503.
49. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-340.